The da Vinci robotic surgery system for the management of endometrial cancer: a single-center experience

The aim of this study was to report our single-center experience of the da Vinci robotic surgery system in the management of endometrial cancer (EC) patients during 2019–2023. We descriptively summarized the preoperative, intraoperative, and postoperative outcomes. Moreover, we conducted subgroup an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of robotic surgery 2024-02, Vol.18 (1), p.89-89, Article 89
Main Authors: Latifah, Hassan M., Khan, Mahmoud Anis, Nadreen, Farah, Latifah, Abdullah, Asaad, Alanoud, Baradwan, Saeed
Format: Article
Language:English
Subjects:
Abdomen
Blood
Body mass index
Cancer
Endometrial cancer
Gynecological surgery
Hernias
Histology
Hospitals
Infections
Laparoscopy
Laparotomy
Lymphatic system
Medicine
Medicine & Public Health
Minimally Invasive Surgery
Obesity
Obstetrics
Patients
Postoperative period
Robotic surgery
Subgroups
Surgery
Surgical outcomes
Tumors
Urology
Vagina
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to report our single-center experience of the da Vinci robotic surgery system in the management of endometrial cancer (EC) patients during 2019–2023. We descriptively summarized the preoperative, intraoperative, and postoperative outcomes. Moreover, we conducted subgroup analyses based on obesity (BMI ≥ 30 kg/m 2 ) and the intraoperative use of indocyanine green dye (ICG). Overall, 100 patients were analyzed. Eighty-five patients (85%) were obese. The mean operative time and estimated blood loss (EBL) were 240.84 ± 70.08 min (range: 110–720) and 104.2 ± 80.3 ml (range: 20–500), respectively. The mean number of retrieved pelvic LNs was 3.01 ± 3.06 (range: 0–15). The use of ICG was employed in 58 (58%). Only a single patient (1%) underwent conversion to laparotomy. Besides, only three (3%) patients experienced vaginal laceration intraoperatively, respectively. The mean hospital stay was 1.34 ± 0.69 days (range: 1–5). No patient experienced postoperative complications. Most tumors had endometrioid histology (82%), grade-1 tumor (49%), and stage-1A disease (67%). At 3-year follow-up, only two patients (2%) developed recurrence. Patients who received the ICG had significantly lower operative time (225.86 vs. 261.52 min, p  = 0.011), estimated blood loss (90 vs. 123.81 ml, p  = 0.037), and hospital stay (1.12 vs. 1.64 days, p  
ISSN:1863-2491
1863-2483
1863-2491
DOI:10.1007/s11701-024-01845-6